piastrinici

Piastrinici is an Italian term used to refer to platelets and platelet-related processes. Platelets are small, anucleate cell fragments circulating in blood, typically 150,000–450,000 per microliter. They originate mainly from megakaryocytes in the bone marrow, under the influence of thrombopoietin, and survive about 7–10 days in circulation.

In hemostasis, piastrinici contribute to the formation of a hemostatic plug. Upon vascular injury, they adhere to exposed collagen and von Willebrand factor via surface receptors such as GPIb-IX-V, undergo shape change, release adenosine diphosphate (ADP), thromboxane A2, and other mediators from their granules, and aggregate through GPIIb/IIIa to form a platelet plug. They also provide a phospholipid surface for coagulation factors that stabilize a fibrin clot.

Abnormal piastrinici counts or function can cause bleeding or thrombosis. Thrombocytopenia is a low platelet count and can result from diverse causes (bone marrow suppression, immune destruction). Thrombocytosis is an elevated count and can be reactive or clonal. Platelet function disorders affect adhesion, secretion, or aggregation without necessarily changing the count. Laboratory evaluation includes complete blood count, peripheral smear, platelet function tests, and specific assays as needed. The mean platelet volume (MPV) and platelet distribution width can offer additional clues.

Therapeutically, antiplatelet drugs target piastrinici to prevent arterial thrombosis: aspirin inhibits thromboxane A2 formation; P2Y12 inhibitors (clopidogrel, ticagrelor) impair ADP signaling; GP IIb/IIIa inhibitors are used in some settings. In thrombocytopenia with bleeding, platelet transfusions may be required. The term piastrinici is used in Italian medical literature to denote platelets and platelet-related processes.